This page shows the latest PI3K news and features for those working in and with pharma, biotech and healthcare.
Following after its first three drugs are potential first-in-class selective Syk inhibitor HMPL-523, in phase 1 testing for non-Hodgkin’s lymphoma, and a PI3K delta inhibitor
Blockbuster potential for PI3K drug. Novartis has gained FDA approval for its PI3K inhibitor Piqray for advanced breast cancer, bucking the trend for the drug class in solid tumour therapy. ... Rival Swiss pharma Roche was also developing a PI3K
among PI3K inhibitors.
Ipatasertib is an oral, targeted drug that binds to all three isoforms of AKT, which blocks the PI3K/AKT signalling pathway and may prevent cancer cell growth and survival. ... The molecule is being studied in tumours that are frequently found to have
Novartis thinks could be down to its high specificity for the PI3K alpha receptor. ... Roche scrapped taselisib for breast cancer after reporting the SANDPIPER results at ASCO, but said it is still interested in pursuing the PI3K mechanism with other
In breast cancer, Novartis will be presenting its SOLAR-1 study of alpha-specific PI3K inhibitor alpelisib (BYL719) in HR+/HER2- advanced breast cancer with PIK3CA mutations, and Clovis Oncology’s
More from news
Approximately 1 fully matching, plus 32 partially matching documents found.
development and commercialisation. 45. Infinity Pharmaceuticals/ Verastem. Duvelisib, oral inhibitor of PI3K‐delta and PI3K‐gamma for haematological cancers (p3).
970. Infinity / AbbVie. Licence and collaboration. IPI-145 an oral PI3K-delta, gamma inhibitor in Phase III for chronic lymphocytic leukaemia .
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
These include CUDC-427, a small molecule antagonist of IAP proteins, and CUDC-907, a dual PI3K and HDAC inhibitor.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...